AXSM vs ORKA: stock comparison and AI forecast
Axsome Therapeutics, Inc. (AXSM) and Oruka Therapeutics, Inc. (ORKA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AXSM Axsome Therapeutics, Inc.
- Market Cap
- $7.18B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ORKA Oruka Therapeutics, Inc.
- Price
- $99.55 +44.4% · 6M
- Market Cap
- $6.71B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- AXSM and ORKA have similar market capitalizations ($7.18B and $6.71B).
- AXSM carries 6.84 times debt per unit of equity, against 0.02 times for ORKA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AXSM | ORKA |
|---|---|---|
| Market Cap | $7.18B | $6.71B |
| P/B Ratio | 68.06x | 6.02x |
| EPS | $-3.05 | $-4.15 |
| Book Value/Share | $2.01 | $16.83 |
| Revenue/Share | $16.52 | – |
| FCF/Share | $-1.58 | $-1.53 |
Profitability & Margins
| Metric | AXSM | ORKA |
|---|---|---|
| ROE | -149.2% | – |
| ROA | -19.0% | – |
| ROIC | -47.6% | -13.9% |
| Gross Margin | 93.2% | – |
| Operating Margin | -17.4% | – |
| Net Margin | -18.2% | – |
| EBT Margin | -18.1% | – |
| Tax Rate | -0.4% | – |
Financial Health
| Metric | AXSM | ORKA |
|---|---|---|
| Current Ratio | 1.42x | 38.51x |
| Quick Ratio | 1.34x | – |
| D/E Ratio | 6.84x | 0.02x |
| Financial Leverage | 7.84x | 1.02x |
| Interest Coverage | 3.2x | -15.9x |
| Working Capital | $215M | $862M |
Cash Flow
| Metric | AXSM | ORKA |
|---|---|---|
| Operating Cash Flow | -$82M | -$101M |
| Free Cash Flow | -$83M | -$101M |
| Capital Spending | -$840K | -$230K |
| FCF/Sales | -9.6% | – |
| CapEx/Sales | 0.1% | – |
Operational Efficiency
| Metric | AXSM | ORKA |
|---|---|---|
| Asset Turnover | 1.05x | – |
| Receivables Turnover | 2.5x | – |
| Inventory Turnover | 1.4x | – |
| Fixed Assets Turnover | 917.6x | – |
| Days Sales Outstanding | 145 days | – |
| Days Inventory | 266 days | – |
| Payables Period | 600 days | – |
| Cash Conversion Cycle | -189 days | – |
Income Statement
| Metric | AXSM | ORKA |
|---|---|---|
| Total Revenue | $865M | – |
| Operating Income | -$151M | -$155M |
| Net Income | -$157M | – |
| R&D Expense | $198M | $129M |
| SG&A Expense | $766M | – |
| Cost of Goods Sold | $58M | – |
Dividend & Shareholder Information
| Metric | AXSM | ORKA |
|---|---|---|
| Shares Outstanding | 52M | 66M |
AXSM vs ORKA: stock comparison and AI forecast
Which is bigger, AXSM or ORKA?
AXSM and ORKA have similar market capitalizations ($7.18B and $6.71B).
Which one does Intratio's AI model rank higher, AXSM or ORKA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.